NCT00336063 2026-03-18
Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
97 trialsNCT00740805 2026-03-18
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01695941 2026-03-18
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02520791 2026-03-18
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03321643 2026-03-18
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03478462 2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT03494569 2026-03-18
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
Phase 1 Suspended
NCT03502733 2026-03-18
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04301076 2026-03-18
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
Phase 1 Suspended
NCT04652960 2026-03-18
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05272384 2026-03-18
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05627245 2026-03-18
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06015880 2026-03-18
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Suspended
NCT06860594 2026-03-18
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06904066 2026-03-18
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07332507 2026-03-18
Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT07444710 2026-03-18
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT07478848 2026-03-18
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
Abramson Cancer Center at Penn Medicine
Phase 1 Not yet recruiting
NCT02160015 2026-03-17
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03528642 2026-03-17
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03547115 2026-03-17
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
Phase 1 Terminated
NCT05397496 2026-03-17
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Novartis
Phase 1 Active not recruiting
NCT06189391 2026-03-17
MK-1045-001
MSD R&D (China) Co., Ltd.
Phase 1 Recruiting
NCT07164560 2026-03-17
Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Recruiting
NCT05131022 2026-03-16
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT06026319 2026-03-16
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Massachusetts General Hospital
Phase 1 Recruiting
NCT06254495 2026-03-16
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
Seagen Inc.
Phase 1 Active not recruiting
NCT06508463 2026-03-16
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT07137494 2026-03-16
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT02390752 2026-03-13
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT03460977 2026-03-13
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Phase 1 Recruiting
NCT04970901 2026-03-13
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
ADC Therapeutics S.A.
Phase 1 Recruiting
NCT05424822 2026-03-13
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06139406 2026-03-13
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06470438 2026-03-13
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06660563 2026-03-13
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06875063 2026-03-13
GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
The First Affiliated Hospital of Xiamen University
Phase 1 Recruiting
NCT07133997 2026-03-13
Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT07295951 2026-03-13
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07308132 2026-03-13
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT05292664 2026-03-12
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05828589 2026-03-12
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
BeOne Medicines
Phase 1 Active not recruiting
NCT05994157 2026-03-12
Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
Y-mAbs Therapeutics
Phase 1 Terminated
NCT07465835 2026-03-12
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
Electra Therapeutics Inc.
Phase 1 Recruiting
NCT01087294 2026-03-11
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT05535855 2026-03-11
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
University of Colorado, Denver
Phase 1 Recruiting
NCT07444632 2026-03-11
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07257419 2026-03-10
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT04573140 2026-03-09
PNOC020
University of Florida
Phase 1 Active not recruiting
NCT06326008 2026-03-09
Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
Beijing GoBroad Hospital
Phase 1 Recruiting